Psoriasis trials in Poland

In Poland 16 Also abroad 274

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Bydgoszcz, Cracow, Lublin, Torun, Warsaw
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Where
Bialystok, Bydgoszcz, Elblag, Pruszków, Warsaw
Age
18 years and over
People
300 worldwide
Run by
AbbVie
See details and how to joinNCT06865105
Phase 1Taking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn, Płońsk, Poznan, Torun, Warsaw, Wroclaw
Age
18 years and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Rzeszów, Sosnowiec, Warsaw
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 3Taking people
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Where
Bialystok, Cracow, Elblag, Gdansk, Gdynia, Katowice, Kielce, Lodz, Lublin, Mikolow, Olsztyn, Ostrowiec Świętokrzyski, Poznan, Rzeszów, Skierniewice, Torun, Warsaw, Warszawa, Wroclaw, ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. Supronik
Age
40 years and over
People
3,040 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Bialystok, Garwolin, Lodz, Lublin, Olsztyn, Warsaw
Age
12 years to 17 years
People
366 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00
Phase 3Taking people
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Kraków, Lodz, Warsaw, Wroclaw
Age
4 years to 18 years
People
153 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00
Phase 3Taking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Bialystok, Białystok, Bytom, Cracow, Dąbrówka, Elblag, Katowice, Lodz, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw
Age
18 years and over
People
1,088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
Phase 3Taking people
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Where
Gdansk, Lodz, Lublin, Rzeszów, Wroclaw
Age
4 years to 17 years
People
110 worldwide
Run by
Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00
Phase 3Taking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Białystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Elblag, Gdynia, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw, Wrocław
Age
18 years and over
People
1,182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Cracow, Lodz, Lublin, Sosnowiec, Warsaw
Age
5 years to 17 years
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
Phase 3Taking people
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Where
Bialystok, Cracow, Elblag, Krakow, Lodz, Osielsko (Bydgoszcz), Poznan, Warsaw, Wroclaw
Age
18 years and over
People
320 worldwide
Run by
Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00
Phase 2/3Taking people
Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome
Where
Olsztyn, Szczecin, Warsaw
Age
18 years and over
People
60
Run by
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
See details and how to join2024-516919-25-00 · EU 2024-516919-25-00
Phase 4Taking people
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Where
Bydgoszcz, Bytom, Elblag, Krakow, Kraków, Lublin, Poznan, Warsaw, Warszawa, Wroclaw
Age
18 years and over
People
100 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Poznan, Wroclaw
Age
18 years to 75 years
People
1,200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693
Phase 3Not yet taking people in Poland
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
Where
Bytom, Gdansk, Lodz, Lublin, Piaseczno, Pruszkow, Wroclaw
Age
18 years and over
People
705 worldwide
Run by
Can-Fite BioPharma
See details and how to joinNCT06643260 · EU 2024-519919-34-00